Molecular Partners AG
SIX:MOLN
Molecular Partners AG
SIX:MOLN
Price:
3.38 CHF
0.9%
Updated:
May 7, 2024
Molecular Partners AG
Cash from Financing Activities
|
Molecular Partners AG
Cash from Financing Activities Peer Comparison
Comparables:
ADCT
CRSP
BSLN
IDIA
KURN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Cash from Financing Activities
-CHf1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Financing Activities
$73.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Financing Activities
$62.7m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Financing Activities
-CHf57.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-20%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash from Financing Activities
CHf162.3m
|
CAGR 3-Years
396%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Financing Activities
-CHf171k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Molecular Partners AG's Cash from Financing Activities?
Cash from Financing Activities
-1.2m
CHF
-1.2m
CHF
Based on the financial report for Dec 31, 2023, Molecular Partners AG's Cash from Financing Activities amounts to -1.2m CHF.
What is Molecular Partners AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
26%
26%
Over the last year, the Cash from Financing Activities growth was 26%.
You don't have any saved screeners yet
